Product Datasheet

Common beta Chain Antibody (CSL311) - (Research Grade Biosimilar) - Low Endotoxin, Azide and BSA Free NBP3-28274-100ug

Unit Size: 100 ug

Store at -20C in powder form. Store at -80C once reconstituted.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP3-28274

Updated 8/14/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NBP3-28274



NBP3-28274-100ug

Common beta Chain Antibody (CSL311) - (Research Grade Biosimilar) - Low Endotoxin, Azide and BSA

Free	
Product Information	
Unit Size	100 ug
Concentration	LYOPH mg/ml
Storage	Store at -20C in powder form. Store at -80C once reconstituted.
Clonality	Monoclonal
Clone	CSL311
Preservative	No Preservative
Reconstitution Instructions	Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Isotype	IgG4
Purity	Protein A purified
Buffer	Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Product Description	
Description	The heavy chain type is hulgG4, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
	This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles. Patent #: WO2023173173A
Host	Human
Gene ID	1439
Gene Symbol	CSF2RB
Species	Human
Immunogen	CSF2Rb / CD131
Endotoxin Note	< 0.001EU/ug,determined by LAL method.
Product Application Details	
Applications	ELISA, Flow Cytometry, Functional

Product Application Details	
Applications	ELISA, Flow Cytometry, Functional
Recommended Dilutions	Flow Cytometry, ELISA, Functional



Images GM-CSF-mediated proliferation of TF-1 can be completely blocked by 120 antibodies with an IC50 of 4.105 nM. -20 0.001 0.01 0.1 10 100 1000 Antibody conc. (nM) Immobilized human CSF2RB His at 2 ug/mL can bind Common beta 2.0 Chain Antibody (CSL311), EC50=0.0122 ug/mL. 1.5 0D420 0.5 0.0 10 0.001 0.01 0.1 Antibody Conc. (μg/mL) IL-3-mediated proliferation of TF-1 can be completely blocked by antibodies with an IC50 of 0.2109 nM. nbition of growth(%) 100 80 60 40 20 0 -20 10 100 1000 0.001 0.01 0.1 Antibody conc. (nM) Human CSF2RB HEK293 cells were stained with Common beta Chain 40000 Antibody (CSL311) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.049 ug/mL. 30000 **₩** 20000 10000 0.001 0.01 0.1 10 100 Antibody conc. (µg/mL)



Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP3-28274-100ug

G-102-C Goat anti-Human IgG Secondary Antibody [Unconjugated]

NB7446 Goat anti-Human IgG Fc Secondary Antibody

DDXCH04P-100 Human IgG4 Isotype Control

NBP2-52244-0.05mg Recombinant Human Common beta Chain His Protein

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP3-28274

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

